Florence Brunet-Possenti, Morgane Weiss, Jean-Luc Prétet, Lydia Deschamps, Vincent Descamps, Caroline Halimi, Diane Descamps, Jade Ghosn, Romane Guilbaud, Charlotte Charpentier, Valentine Marie Ferré
{"title":"Detection of alpha-HPV types in cutaneous squamous cell carcinoma associated with markers of carcinogenesis: a retrospective study.","authors":"Florence Brunet-Possenti, Morgane Weiss, Jean-Luc Prétet, Lydia Deschamps, Vincent Descamps, Caroline Halimi, Diane Descamps, Jade Ghosn, Romane Guilbaud, Charlotte Charpentier, Valentine Marie Ferré","doi":"10.1093/ced/llaf264","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While the role of oncogenic alpha (α)-HPVs in anogenital and oral mucosal cancers is well-established, their involvement in skin carcinogenesis remains unexplored.</p><p><strong>Objective: </strong>To investigate the role of α-HPV in cutaneous squamous cell carcinoma (cSCC).</p><p><strong>Methods: </strong>This retrospective study included 129 formalin-fixed, paraffin-embedded cSCC samples. The main outcomes were the proportion of α-HPV positive cSCC and the characterization of viral features, assessed through HPV typing and viral DNA integration analysis.</p><p><strong>Results: </strong>The study included 99 cases of invasive cSCCs and 30 Bowen's disease. HPV DNA was detected in 56.6% of samples. HPV from the α genus were identified in 25 samples, (19.4%), with only a single α-HPV type detected in each positive sample. HPV16 was the main type, detected in 10 samples. Peripheral healthy skin tested negative in 10 out of 11 α-HPV-positive samples. Viral DNA was integrated in host-cell DNA in 8 out of 9 HPV16-positive samples.</p><p><strong>Conclusions: </strong>This study highlights a significant prevalence of α-HPV-positive samples among both invasive and in situ cSCC. The virological findings support a carcinogenic role of α-HPV in cSCC.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf264","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: While the role of oncogenic alpha (α)-HPVs in anogenital and oral mucosal cancers is well-established, their involvement in skin carcinogenesis remains unexplored.
Objective: To investigate the role of α-HPV in cutaneous squamous cell carcinoma (cSCC).
Methods: This retrospective study included 129 formalin-fixed, paraffin-embedded cSCC samples. The main outcomes were the proportion of α-HPV positive cSCC and the characterization of viral features, assessed through HPV typing and viral DNA integration analysis.
Results: The study included 99 cases of invasive cSCCs and 30 Bowen's disease. HPV DNA was detected in 56.6% of samples. HPV from the α genus were identified in 25 samples, (19.4%), with only a single α-HPV type detected in each positive sample. HPV16 was the main type, detected in 10 samples. Peripheral healthy skin tested negative in 10 out of 11 α-HPV-positive samples. Viral DNA was integrated in host-cell DNA in 8 out of 9 HPV16-positive samples.
Conclusions: This study highlights a significant prevalence of α-HPV-positive samples among both invasive and in situ cSCC. The virological findings support a carcinogenic role of α-HPV in cSCC.
期刊介绍:
Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.